Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a leading biotechnology company focusing on the development of messenger RNA medicines for rare liver and respiratory diseases, as well as vaccines for infectious diseases, recently unveiled its third-quarter earnings for 2025. The company showcased a better-than-expected performance despite a challenging market environment, continuing to make strides in its financial and operational metrics.
On November 10, 2025, Arcturus reported an earnings per share (EPS) of -$0.49, marking a significant improvement over the estimated EPS of -$0.80 and a 60.8% earnings surprise compared to the Zacks Consensus Estimate of a loss of $1.25 per share. Although the company had a loss of $0.26 per share in the same quarter last year, it has exceeded consensus EPS estimates three times in the past four quarters.
The company's revenue for the quarter was $17.15 million, surpassing the estimated $16.03 million and exceeding the Zacks Consensus Estimate by 50.63%. However, this represents a decline from the $41.67 million reported in the same quarter the previous year. Despite this decline, Arcturus has managed to exceed consensus revenue estimates three times in the last four quarters, demonstrating its ability to outperform market expectations.
Arcturus's financial metrics reveal a mixed picture. The company has a negative price-to-earnings (P/E) ratio of approximately -3.96, indicating negative earnings. However, its price-to-sales ratio of about 2.03 suggests that investors are willing to pay $2.03 for every dollar of the company's sales. The enterprise value to sales ratio is 0.55, which may imply a relatively low valuation compared to its sales. Additionally, the debt-to-equity ratio of 0.10 shows a low level of debt, while a current ratio of 5.90 indicates strong liquidity.
During the Q3 2025 earnings call, key company figures, including CEO Joseph Payne and CFO Andrew Sassine, discussed the company's financial performance and strategic direction with analysts from prominent financial institutions. This engagement with analysts and investors underscores the company's commitment to transparency and growth, including the initial findings of the ARCT-032 clinical activity, which were presented to the cystic fibrosis community.
